The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas

R. Briski, Andrew L Feldman, N. G. Bailey, M. S. Lim, K. Ristow, Thomas Matthew Habermann, W. R. Macon, D. J. Inwards, J. P. Colgan, Grzegorz S Nowakowski, M. S. Kaminski, Thomas Elmer Witzig, Stephen Maxted Ansell, R. A. Wilcox

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Peripheral T-cell lymphomas (PTCLs) are a heterogenous group of aggressive non-Hodgkin's lymphomas that are incurable in the majority of patients with current therapies. Outcomes associated with anthracycline-based therapies are suboptimal, but remain the standard of care for most patients, even though the benefits of this approach remain uncertain. This study retrospectively examined outcomes in a cohort of North American PTCL patients treated with both anthracycline-and nonanthracycline-containing regimens. The incorporation of anthracycline-containing regimens was associated with improved progression-free survival (PFS) and overall survival (OS). Patients treated with nonanthracycline-containing regimens were more likely to have high-risk features and were less likely to undergo high-dose therapy and stem cell transplantation. However, anthracycline use remained an independent predictor of improved PFS and OS when adjusting for these confounding variables. Anthracycline-based regimens and consolidation with high-dose therapy and autologous stem cell transplantation in appropriately selected patients remains a viable option for patients unable to participate in a clinical trial. Long-term disease-free survival is not optimal, highlighting the need for an improved understanding of disease pathogenesis, and the development of novel therapeutic strategies.

Original languageEnglish (US)
Article numbere214
JournalBlood Cancer Journal
Volume4
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Peripheral T-Cell Lymphoma
Anthracyclines
Drug Therapy
Disease-Free Survival
Stem Cell Transplantation
Therapeutics
Confounding Factors (Epidemiology)
Survival
Standard of Care
Non-Hodgkin's Lymphoma
Clinical Trials

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. / Briski, R.; Feldman, Andrew L; Bailey, N. G.; Lim, M. S.; Ristow, K.; Habermann, Thomas Matthew; Macon, W. R.; Inwards, D. J.; Colgan, J. P.; Nowakowski, Grzegorz S; Kaminski, M. S.; Witzig, Thomas Elmer; Ansell, Stephen Maxted; Wilcox, R. A.

In: Blood Cancer Journal, Vol. 4, No. 5, e214, 2014.

Research output: Contribution to journalArticle

Briski, R. ; Feldman, Andrew L ; Bailey, N. G. ; Lim, M. S. ; Ristow, K. ; Habermann, Thomas Matthew ; Macon, W. R. ; Inwards, D. J. ; Colgan, J. P. ; Nowakowski, Grzegorz S ; Kaminski, M. S. ; Witzig, Thomas Elmer ; Ansell, Stephen Maxted ; Wilcox, R. A. / The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. In: Blood Cancer Journal. 2014 ; Vol. 4, No. 5.
@article{ec594521753147a3b2e82341fde15b62,
title = "The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas",
abstract = "Peripheral T-cell lymphomas (PTCLs) are a heterogenous group of aggressive non-Hodgkin's lymphomas that are incurable in the majority of patients with current therapies. Outcomes associated with anthracycline-based therapies are suboptimal, but remain the standard of care for most patients, even though the benefits of this approach remain uncertain. This study retrospectively examined outcomes in a cohort of North American PTCL patients treated with both anthracycline-and nonanthracycline-containing regimens. The incorporation of anthracycline-containing regimens was associated with improved progression-free survival (PFS) and overall survival (OS). Patients treated with nonanthracycline-containing regimens were more likely to have high-risk features and were less likely to undergo high-dose therapy and stem cell transplantation. However, anthracycline use remained an independent predictor of improved PFS and OS when adjusting for these confounding variables. Anthracycline-based regimens and consolidation with high-dose therapy and autologous stem cell transplantation in appropriately selected patients remains a viable option for patients unable to participate in a clinical trial. Long-term disease-free survival is not optimal, highlighting the need for an improved understanding of disease pathogenesis, and the development of novel therapeutic strategies.",
author = "R. Briski and Feldman, {Andrew L} and Bailey, {N. G.} and Lim, {M. S.} and K. Ristow and Habermann, {Thomas Matthew} and Macon, {W. R.} and Inwards, {D. J.} and Colgan, {J. P.} and Nowakowski, {Grzegorz S} and Kaminski, {M. S.} and Witzig, {Thomas Elmer} and Ansell, {Stephen Maxted} and Wilcox, {R. A.}",
year = "2014",
doi = "10.1038/bcj.2014.34",
language = "English (US)",
volume = "4",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas

AU - Briski, R.

AU - Feldman, Andrew L

AU - Bailey, N. G.

AU - Lim, M. S.

AU - Ristow, K.

AU - Habermann, Thomas Matthew

AU - Macon, W. R.

AU - Inwards, D. J.

AU - Colgan, J. P.

AU - Nowakowski, Grzegorz S

AU - Kaminski, M. S.

AU - Witzig, Thomas Elmer

AU - Ansell, Stephen Maxted

AU - Wilcox, R. A.

PY - 2014

Y1 - 2014

N2 - Peripheral T-cell lymphomas (PTCLs) are a heterogenous group of aggressive non-Hodgkin's lymphomas that are incurable in the majority of patients with current therapies. Outcomes associated with anthracycline-based therapies are suboptimal, but remain the standard of care for most patients, even though the benefits of this approach remain uncertain. This study retrospectively examined outcomes in a cohort of North American PTCL patients treated with both anthracycline-and nonanthracycline-containing regimens. The incorporation of anthracycline-containing regimens was associated with improved progression-free survival (PFS) and overall survival (OS). Patients treated with nonanthracycline-containing regimens were more likely to have high-risk features and were less likely to undergo high-dose therapy and stem cell transplantation. However, anthracycline use remained an independent predictor of improved PFS and OS when adjusting for these confounding variables. Anthracycline-based regimens and consolidation with high-dose therapy and autologous stem cell transplantation in appropriately selected patients remains a viable option for patients unable to participate in a clinical trial. Long-term disease-free survival is not optimal, highlighting the need for an improved understanding of disease pathogenesis, and the development of novel therapeutic strategies.

AB - Peripheral T-cell lymphomas (PTCLs) are a heterogenous group of aggressive non-Hodgkin's lymphomas that are incurable in the majority of patients with current therapies. Outcomes associated with anthracycline-based therapies are suboptimal, but remain the standard of care for most patients, even though the benefits of this approach remain uncertain. This study retrospectively examined outcomes in a cohort of North American PTCL patients treated with both anthracycline-and nonanthracycline-containing regimens. The incorporation of anthracycline-containing regimens was associated with improved progression-free survival (PFS) and overall survival (OS). Patients treated with nonanthracycline-containing regimens were more likely to have high-risk features and were less likely to undergo high-dose therapy and stem cell transplantation. However, anthracycline use remained an independent predictor of improved PFS and OS when adjusting for these confounding variables. Anthracycline-based regimens and consolidation with high-dose therapy and autologous stem cell transplantation in appropriately selected patients remains a viable option for patients unable to participate in a clinical trial. Long-term disease-free survival is not optimal, highlighting the need for an improved understanding of disease pathogenesis, and the development of novel therapeutic strategies.

UR - http://www.scopus.com/inward/record.url?scp=84901988214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901988214&partnerID=8YFLogxK

U2 - 10.1038/bcj.2014.34

DO - 10.1038/bcj.2014.34

M3 - Article

VL - 4

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 5

M1 - e214

ER -